

# Biological Agents Index

Risk Management Strategies for Infectious Disease Surge



FOURTH EDITION

Author

N. Robert Olisa, III  
MPA; MS; M (ASCP); RM (NRM)



# Biological Agents Index

---

## Risk Management Strategies for Contagions

Achieving cost-effective outcomes using macroeconomics and microbiology, in addition to new public management concepts for implementation and evaluation of best practices in community based sanitation, health promotion, large scale antibiotics and vaccines manufacturing, and laboratory analytical platforms

### **FOURTH EDITION**

N. Robert Olisa, III  
MPA; MS; M (ASCP); RM (NRCM)

Adjunct Professor, Biological Sciences  
Prince Georges County Community College  
Largo, MD, USA

Chief Executive Officer  
Olisa Research Corporation  
Las Cruces, New Mexico, USA

American Journal of Biological Defense ®

Las Cruces, New Mexico

**ISBN** 978-0-9815543-4-1; 978-0-9815543-6-5 (Print, Hard Cover 252 pages Revised)  
**ISBN** 978-0-9815543-1-0 (Software)

**Publishing Headquarters**

American Journal of Biological Defense Press  
2521 N. Main Street, Unit 1 Suite 206  
Las Cruces, NM 88001

**Worldwide Web**

<http://www.BiologicalAgents.com>

Copyright © 2002, 2003, 2007, 2008, 2009 (Revised), 2010. *The American Journal of Biological Defense*. All Rights Reserved.

**Library of Congress Control Number:** 2010915985

The Publisher offers generous price reductions on this book when ordered in bulk quantities. Please contact sales director using the address above.

This book maybe duplicated for academic citation purposes. Unauthorized duplication of this book in part or whole is illegal. Violators will be prosecuted under existing US, and or international laws as applicable.

**PRINTED IN UNITED STATES**

*To those stricken, or burdened by cancer.*

# CONTENTS

ABOUT THE AUTHOR.....	vi
ACKNOWLEDGEMENTS.....	vii
PREFACE.....	ix

## PART I: BASIC CONCEPTS

### CHAPTER ONE

#### CONCEPTS IN MACROECONOMICS AND NEW PUBLIC MANAGEMENT

1. MACROECONOMICS.....	1
2. NEW PUBLIC MANAGEMENT.....	2
3. STRATEGIC PLANNING.....	4
4. POLICY ANALYSIS.....	5
5. RISK ASSESSMENTS.....	8
6. NEEDS ASSESSMENTS.....	10
7. SELECTING, AND MANAGING A WORKFORCE.....	12
8. PROGRAM INPUTS, OUTPUTS, AND OUTCOMES.....	17
9. PERFORMANCE BUDGETING.....	19
10. BENCHMARKING AND PROCESS EVALUATION.....	20
11. COST-BENEFIT AND COST-EFFECTIVE ANALYSIS.....	26

### CHAPTER TWO

#### CONCEPTS IN MICROBIOLOGY

1. BACTERIA: A HISTORICAL PERSPECTIVE.....	34
2. BIOCHEMISTRY OF BACTERIA.....	35
3. DETECTING AND IDENTIFYING BACTERIA.....	42
4. ECOLOGICAL RELATIONSHIPS IN BACTERIA.....	54
5. GENETICS.....	56
6. VIRUSES.....	66
7. INFECTIOUS PARTICLES AND DISEASE.....	70
8. MICROBIAL MASS ACTION PRINCIPLE: THE OUTBREAK COEFFICIENT.....	74
9. INFECTION CONTROL.....	76
10. ANTIBIOTICS AND VACCINES.....	79
11. IMMUNOLOGY.....	84
12. BIOINFORMATICS AND COMPUTATIONAL BIOLOGY.....	87
13. EPIDEMIOLOGY.....	88
14. EPIDEMIOLOGIC TRANSITION THEORY.....	90
15. HEALTH PROMOTION.....	92

## **PART II: BEST PRACTICES**

### **CHAPTER THREE**

#### **APPLICATION OF INFORMATION SYSTEMS (IT) IN DIAGNOSTIC, AND THERAPEUTIC RESEARCH PLATFORMS**

1. INTRODUCTION.....	96
2. PROTEOMICS AND GENOMICS: BASIC METHODOLOGY.....	99
3. TOTAL QUALITY MANAGEMENT AND VALIDATION FOR THE LABORATORY.....	127
4. ESTIMATING INFECTION SURGE .....	136
5. INFECTIOUS DISEASE SURVEILLANCE .....	145

### **CHAPTER FOUR**

#### **PROGRAM EVALUATION STRATEGIES FOR INFECTIOUS DISEASE INTERVENTIONS**

1. INTRODUCTION.....	152
2. SOCIAL AND ECONOMIC DEVELOPMENT PROGRAM EVALUATION.....	155
3. SANITATION AND HEALTH PROMOTION PROGRAM EVALUATION.....	160

## **PART III: CASE STUDIES**

### **CHAPTER FIVE**

1. <b>SYNOPSIS ONE:</b> EVALUATING IMPACTS OF SOCIO-ECONOMIC DEVELOPMENT ON NEW AND OLD CASES OF TB IN EL PASO.....	170
2. <b>SYNOPSIS TWO:</b> EVALUATING IMPACTS OF PERFORMANCE MEASUREMENTS IN FINANCE AND BUDGETING OF TB INTERVENTIONS IN EL PASO.....	177
<b>SYNOPSIS THREE:</b> EVALUATING IMPACTS OF HOSPITAL AND HEALTHCARE APPROPRIATIONS ON NURSE RETENTION IN EL PASO.....	195
3. <b>SYNOPSIS FOUR:</b> PLANNING FOR PANDEMIC FLU OUTBREAKS IN EL PASO.....	204
4. <b>PRACTICE</b> .....	216
<b>INDEX</b> .....	229

## **ABOUT THE AUTHOR**

Robert Olisa is Chief Executive of Olisa Research (formerly Biological Agents Corporation or BAC), manufacturers of early cancer diagnostics and natural immunity boosting therapeutics and supplements. Additionally, Robert founded Olisa Foundation in 2006. The foundation is a Texas Non-Profit Organization, and Non-Governmental Organization operating in the Americas and Africa. The goal of the foundation is to reduce threats of disease, conflict, and starvation by improving quality of life of the workforce. To achieve this, the foundation promotes the use of information and biological technologies. The foundation is also the parent company of Olisa Research. Another subsidiary, American Journal of Biological Defense publishes the Biological Agents Index and SurgeForcats1.0. In 2002, Robert formulated a standard online algorithm used in contagion risk management. The same year he was awarded the first US patent for a utility in proteomics. Robert was born in Nigeria but immigrated to the US in 1971. He is from El Paso Texas and serves in the United States Naval Reserves, and is an Adjunct Professor at Prince Georges County Community College, Maryland.

## ACKNOWLEDGEMENTS

This book has been the product of numerous institutional collaborations and team work. I owe a debt of gratitude to the faculty of Natural and Medical Sciences at the University of Jos, Nigeria where my early curiosity in biotechnology and science was ignited; the United States Department of Defense where my interest in biotechnology was developed.

Furthermore, I would like to acknowledge the distinguished fellows, current and past board members of the Olisa Foundation specifically Janine Y. Schneider, Peter J. Terek, and Yvonne Thelwell. Thanks to the faculty of the Graduate School of Biology, University of Texas El Paso; Graduate School of Public Health; the Open University at the San Diego State University; Minority Biomedical Research Team at the National Institutes of Health and Department of Microbiology, Graduate School of Medicine at Howard University; and Howard University Hospital for awarding me the Charles S. Ireland “first place prize” for part of the research that went into this book; Hans-Peter Fiedler and faculty of the Institute für Mikrobiologie und Membrane Physiologie, Universitaet Tübingen, Germany, where I spent three years of study abroad to develop Olisferrol; the faculty of Biological Sciences, City College, San Diego, and Prince Georges County Community College where I developed material for teaching concepts in microbiology; the faculty of the Institute for Policy and Economic Development, University of Texas El Paso, where I developed material for teaching macroeconomics and new public management.

In addition, I would like to thank the following for providing some guideline materials, criticisms, and reviews used in preparing the manuscripts of this book: Sergo Pena, Karl Roberts, Karen Lyon, Elizabeth Dalton, and William Weaver. In addition, I would like to thank the following for their technical support or for providing some of the Multiple Drug Resistant Clinical Isolates used in the research of this book: Thomas Halder, and Michael Betzler. Furthermore, I would also like to acknowledge unknown contributors of the online encyclopedia Wikipedia for providing some of the definitions used in the preparation of this manuscript. In addition I would like to thank Takashi Inoue for meticulously proofing algorithms in the Biological Agents Index and Stanly Tai, Volkmar Braun, Allen Douglas, and Elaine Fredericksen for reading all or part of the manuscript of this book. Finally, I would like to thank Paul F. Kahle at the Institut für Tropenmedizin, Universitaet Tübingen, Germany, and Elie Mavoungou a former Senior Research scientist with Albert Schweitzer Hospital, Lambbaréné, Gabon for their input in reviewing this book. Research into this book was entirely funded by grants from the Olisa Foundation.

**N. Robert Olisa, III**  
El Paso, Texas

## PREFACE

Until now, this millennia has seen major and meteoric advances in socio-economic and biological sciences like, but not limited to, concepts in Game Theory; Organizational Theories like Transformation, and Computational Biology. In addition, there have been numerous discoveries that have brought increases in the understanding and links between the emergence of new and old cases of infectious disease (incidence and prevalence), economic development, and the democracy. Interestingly, these links have been drawn between outbreaks of conflict, famine, and contagions. What is known is that democracies reduce risks of conflict, increase economic development, and reduce prevalence to infectious disease. Consequently, infectious disease intervention programs should contain both socio-economic and biomedical inputs and outputs in order to achieve effective outcomes.

Accordingly, to effectively manage these programs, managers should be familiar with concepts in macroeconomics, microbiology, and new public management. For the most part, origins of modern socio-economic and biology concepts date as far back as the 1950s, '60s, and '70s. The global economic recession; and increasing globalization have ably assisted in shaping the way global interventions against contagions are planned and managed. There have been numerous lessons learned. For one thing, it is more cost effective and cost beneficial to replace labor with technology (new public management). Secondly, and consequently, highly effective governments tend to outsource social and public programs and play a greater role in regulation and oversight. Subsequently, the private sector (corporations and non-profit organizations) are increasingly participating in program implementation.

Biological Agents Index (Fourth Edition) has been written for performers in government agencies, public, non-profit, and private sectors and for students of management and public policy. *Biological Agents Index* stresses the need for increased reliance on information technologies for cost-effective management and discusses best practices of using bioinformatics in implementing, assessing, evaluating socio-economic and biomedical technology programs, specifically pharmaceutical, public health, and clinical laboratory diagnostics platforms. Like *Lean Six Sigma*, the Index can be used to identify constraint within infectious disease intervention processes. This information can be used to reduce threats to validity and variation when implementing specific programs. If correctly used, the index can ably assist the user in the implementation of leaner processes, and in conducting more accurate program evaluations.

During the preparation of this edition, previous and current authors and works have been cited at the end of each part. In addition, other contributors have been documented in the acknowledgement section. This edition has been written to provide the user basic skills needed to be effective in the evaluation of socio-economic and or biomedical technology intervention programs against infectious disease in urban and rural communities. In addition, this edition can supplement the user's education and experience in infectious disease healthcare management or serve as a handbook for future reference. To achieve these goals, this edition has been arranged into three parts with five chapters. The first part discusses basic concepts in macroeconomics, new public management, and microbiology. In addition, the chapters in Part One outline basic management concepts in strategic planning and attempts to demystify microbiology and its components: bacteriology, virology, biotechnology, immunology, and bioinformatics. Furthermore, suggestions are made on how concepts in Part One can be used as tools in the implementation, analysis, and evaluation associated with strategic planning concepts like inputs, outputs, and outcomes, and program assessments and analysis. Part Two of this book offers suggestions on the best way to approach managing best practices in the area of infectious diseases infection control and health promotion programs using administrative processes like outreach, rural economic development, sanitation, and laboratory quality management. Finally, Part Three delivers series of realistic synopses and case studies that places the reader in realistic management crisis situations.

Finally, this book is currently being reviewed for a fifth edition. Readers with suggestions for improvement and interested scholarly contributors can submit book chapter inputs or paper publications to: [info@biologicalagents.com](mailto:info@biologicalagents.com).

**N. Robert Olisa**, Editor